Treatment of diffuse large-cell lymphoma with anti-CD20 antibody
AssigneeBiogen, Inc.
InventorsChristine A. White, Antonio J. Grillo-Lopez
Life of this patent
Estimating the term…
Abstract
The present invention concerns methods for the treatment of diffuse large cell lymphoma by administration of an anti-CD20 antibody and chemotherapy. Particular embodiments include the administration of anti-CD20 antibody in combination with chemotherapy comprising CHOP (cyclophosphamide, hydroxydaunorubicin/doxorubicin, vincristine, and prednisone/prednisolone) and/or in combination with a transplantation regimen.
Claims1
A method of treating a human patient with diffuse large cell lymphoma comprising administering rituximab and CHOP (cyclophosphamide, hydroxydaunorubicin/doxorubicin, vincristine, and prednisone/prednisolone) to the patient, wherein the rituximab is administered on Day 1 of each chemotherapy cycle and the CHOP is administered on Day 1 of each chemotherapy cycle, wherein the patient is >60 years old and has bulky disease (tumor>10 cm in diameter).
Dependencies are inferred from the claim text.